Found 18 matching trials
Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema
PHASE3The purpose of this study is to assess the efficacy and safety of Icatibant...
Location
Georgetown University Hospital, Lombardi Cancer Center
Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
PHASE2This study evaluates the efficacy of orally administered deucrictibant for ...
A Locally Injected Bradykinin Antagonist for TReatment of OSteoarthritiS
PHASE2The purpose of this study is to determine whether intra-articular (knee joi...
Location
Centre Hospitalier Régional - Hôpital Porte Madeleine
Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3
NAThe purpose of the study is to determine if giving isosorbide,a drug that i...
Location
Vanderbilt University Medical Center-GCRC
Tissue Kallikrein Preventing the Restenosis After Stenting of Symptomatic MCA Atherosclerotic Stenosis
PHASE2The study aims to determine whether tissue kallikrein (TK) is efficacy for ...
Location
Department of Neurology, Jinling Hospital, Nanjing University School of Medicine
Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)
PHASE2Large vessel vasculitis (LVV) is a disease that causes damage to blood vess...
Location
University of Edinburgh
Tissue Kallikrein Protect Against Ischemic Stroke
N/AThe results of previous studies were used to assess the causal association ...
Location
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Thrombus Formation Under Different Flow-conditions
N/ARationale: Cardiovascular diseases are important causes of morbidity and mo...
Location
Maastricht University
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
PHASE3This is a Phase 3, multicenter, randomized, double-blind, placebo-controlle...
Status
Active Not Recruiting
Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II
PHASE2This study evaluates the safety and efficacy of PHA-022121 administered ora...